Exploring easily accessible neurophysiological biomarkers for predicting Alzheimer's disease progression: a systematic review.

IF 7.9 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's Research & Therapy Pub Date : 2024-11-04 DOI:10.1186/s13195-024-01607-4

Matteo Costanzo, Carolina Cutrona, Giorgio Leodori, Leonardo Malimpensa, Fabrizia D'antonio, Antonella Conte, Daniele Belvisi

{"title":"Exploring easily accessible neurophysiological biomarkers for predicting Alzheimer's disease progression: a systematic review.","authors":"Matteo Costanzo, Carolina Cutrona, Giorgio Leodori, Leonardo Malimpensa, Fabrizia D'antonio, Antonella Conte, Daniele Belvisi","doi":"10.1186/s13195-024-01607-4","DOIUrl":null,"url":null,"abstract":"<p><p>Alzheimer disease (AD) remains a significant global health concern. The progression from preclinical stages to overt dementia has become a crucial point of interest for researchers. This paper reviews the potential of neurophysiological biomarkers in predicting AD progression, based on a systematic literature search following PRISMA guidelines, including 55 studies. EEG-based techniques have been predominantly employed, whereas TMS studies are less common. Among the investigated neurophysiological measures, spectral power measurements and event-related potentials-based measures, including P300 and N200 latencies, have emerged as the most consistent and reliable biomarkers for predicting the likelihood of conversion to AD. In addition, TMS-based indices of cortical excitability and synaptic plasticity have also shown potential in assessing the risk of conversion to AD. However, concerns persist regarding the methodological discrepancies among studies, the accuracy of these neurophysiological measures in comparison to established AD biomarkers, and their immediate clinical applicability. Further research is needed to validate the predictive capabilities of EEG and TMS measures. Advancements in this area could lead to cost-effective, reliable biomarkers, enhancing diagnostic processes and deepening our understanding of AD pathophysiology.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":null,"pages":null},"PeriodicalIF":7.9000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533378/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's Research & Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13195-024-01607-4","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Alzheimer disease (AD) remains a significant global health concern. The progression from preclinical stages to overt dementia has become a crucial point of interest for researchers. This paper reviews the potential of neurophysiological biomarkers in predicting AD progression, based on a systematic literature search following PRISMA guidelines, including 55 studies. EEG-based techniques have been predominantly employed, whereas TMS studies are less common. Among the investigated neurophysiological measures, spectral power measurements and event-related potentials-based measures, including P300 and N200 latencies, have emerged as the most consistent and reliable biomarkers for predicting the likelihood of conversion to AD. In addition, TMS-based indices of cortical excitability and synaptic plasticity have also shown potential in assessing the risk of conversion to AD. However, concerns persist regarding the methodological discrepancies among studies, the accuracy of these neurophysiological measures in comparison to established AD biomarkers, and their immediate clinical applicability. Further research is needed to validate the predictive capabilities of EEG and TMS measures. Advancements in this area could lead to cost-effective, reliable biomarkers, enhancing diagnostic processes and deepening our understanding of AD pathophysiology.

查看原文本刊更多论文

探索用于预测阿尔茨海默病进展的简便神经生理学生物标志物：系统综述。

阿尔茨海默病（AD）仍然是全球关注的重大健康问题。从临床前阶段发展到明显痴呆已成为研究人员关注的关键点。本文根据 PRISMA 指南进行了系统的文献检索，包括 55 项研究，在此基础上回顾了神经电生理生物标志物在预测阿尔茨海默病进展方面的潜力。其中主要采用了基于脑电图的技术，而 TMS 研究则较为少见。在所研究的神经生理学测量中，频谱功率测量和基于事件相关电位的测量（包括 P300 和 N200 潜伏期）已成为预测向 AD 转换可能性的最一致、最可靠的生物标志物。此外，基于 TMS 的皮质兴奋性和突触可塑性指标也显示出评估向 AD 转换风险的潜力。然而，研究方法上的差异、这些神经电生理指标与已确定的 AD 生物标志物相比的准确性及其直接的临床适用性仍然令人担忧。需要进一步研究来验证脑电图和 TMS 测量的预测能力。这一领域的研究进展可能会带来具有成本效益、可靠的生物标志物，从而加强诊断过程并加深我们对注意力缺失症病理生理学的理解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's Research & Therapy 医学-神经病学

CiteScore

13.10

自引率

3.30%

发文量

172

审稿时长

>12 weeks

期刊介绍： Alzheimer's Research & Therapy is an international peer-reviewed journal that focuses on translational research into Alzheimer's disease and other neurodegenerative diseases. It publishes open-access basic research, clinical trials, drug discovery and development studies, and epidemiologic studies. The journal also includes reviews, viewpoints, commentaries, debates, and reports. All articles published in Alzheimer's Research & Therapy are included in several reputable databases such as CAS, Current contents, DOAJ, Embase, Journal Citation Reports/Science Edition, MEDLINE, PubMed, PubMed Central, Science Citation Index Expanded (Web of Science) and Scopus.